Carriage Inn Of Steubenville Medicare and Medicaid Location: 3102 St Charles Drive, Steubenville, Ohio 43952 Ratings: Phone: (740) 264-7161 |
Lancia Villa Royale Medicare and Medicaid Location: 1852 Sinclair Avenue, Steubenville, Ohio 43953 Ratings: Phone: (740) 264-7101 |
Trinity Skilled Care Center Medicare and Medicaid Location: 380 Summit Avenue, Steubenville, Ohio 43952 Ratings: Phone: (740) 283-7080 |
Catherine's Care Center, Inc Medicare and Medicaid Location: 717 North Sixth Street, Steubenville, Ohio 43952 Ratings: Phone: (740) 282-3605 |
Steubenville Country Club Manor Medicare and Medicaid Location: 575 Lovers Lane, Steubenville, Ohio 43953 Ratings: Phone: (740) 266-6118 |
Laurels Of Steubenville The Medicare and Medicaid Location: 500 Stanton Boulevard, Steubenville, Ohio 43952 Ratings: Phone: (740) 264-5042 |
Villa Vista Royale Llc Medicare and Medicaid Location: 1800 Sinclair Avenue, Steubenville, Ohio 43953 Ratings: Phone: (740) 264-7301 |
News Archive
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).
› Verified 3 days ago